VDN | Vaccine Pipeline
Sponsor & Developer Portfolio

Novavax

Clinical development pipeline, platform architecture, and registered trial tracking for Novavax vaccine candidates.

7
Candidates
3
Target Diseases
5
Linked Studies

Development Phase Distribution

Discontinued / Inactive: 4 Phase 3 Clinical Trial: 2 Approved / Licensed: 1

Platform Technologies

Biological (unspecified platform): 4 Protein nanoparticle + Matrix-M: 1 See FDA product page / label: 1 Protein / subunit: 1

Target Pathogens & Indications

COVID-19 Influenza Seasonal influenza + COVID-19 (combination)

Vaccine Pipeline Candidates (7)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Approved / Licensed fda-nuvaxovid

NUVAXOVID

Target: COVID-19

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication
View Full Clinical Profile → Disease Hub →
Discontinued / Inactive ctgov-nanoflu-quad-niv-novavax

Fluzone HD

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-04-26 (registry estimate)
View Full Clinical Profile → Disease Hub →
Discontinued / Inactive ctgov-coformulated-cic-vaccine-novavax

Fluzone HD trivalent

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2025-11-16 (registry estimate)
View Full Clinical Profile → Disease Hub →
Discontinued / Inactive ctgov-sii-b-1-351-novavax

SII B.1.351

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2022-08 (registry estimate)
View Full Clinical Profile → Disease Hub →
Discontinued / Inactive ctgov-tniv-1-and-matrix-m-adjuvant-novavax

tNIV 1 and Matrix-M Adjuvant

Target: COVID-19

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2025-02-04 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial novavax-flu-covid

COVID-Influenza Combination (CIC) — Novavax

Target: Seasonal influenza + COVID-19 (combination)

Platform: Protein nanoparticle + Matrix-M

Key Milestone: Phase 3 data and potential regulatory path (company projection — verify latest filings)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-nvx-cov2705-novavax

NVX-CoV2705

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-11-18 (registry estimate)
View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →